Real-world treatments and outcomes of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: a Japanese claims analysis
Retrospective analysis identifies treatment regimens and health outcomes in patients with cGVHD, indicating care challenges.
Key Points
The aim is to analyze real-world treatment practices and outcomes for chronic graft-versus-host disease (cGVHD) following allogeneic hematopoietic stem cell transplantation.
Analyzed anonymized Japanese medical insurance claims data
Included 1090 patients with cGVHD
Evaluated systemic treatments and their re-initiation rates
81% of patients received systemic immunosuppressive treatment, primarily with tacrolimus and steroids.
44% received second-line treatment, with steroid addition being the most common approach.
79% had treatment temporarily discontinued, with about half re-initiating treatment; lower rates of re-initiation observed in younger and umbilical cord blood recipients.